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Abstract
Background: Decreased nitric oxide (NO) and hypoargininemia are associated with severe falciparum malaria and may
contribute to severe disease. Intravenous L-arginine increases endothelial NO in moderately-severe malaria (MSM) without
adverse effects. The safety, efficacy and pharmacokinetics of L-arginine or other agents to improve NO bioavailability in
severe malaria have not been assessed.
Methods: In an open-label pilot study of L-arginine in adults with severe malaria (ARGISM-1 Study), patients were
randomized to 12 g L-arginine hydrochloride or saline over 8 hours together with intravenous artesunate. Vital signs,
selected biochemical measures (including blood lactate and L-arginine) and endothelial NO bioavailability (using reactive
hyperemia peripheral arterial tonometry [RH-PAT]) were assessed serially. Pharmacokinetic analyses of L-arginine
concentrations were performed using NONMEM.
Results: Six patients received L-arginine and two saline infusions. There were no deaths in either group. There were no
changes in mean systolic (SBP) and diastolic blood pressure (DBP) or other vital signs with L-arginine, although a transient
but clinically unimportant mean maximal decrease in SBP of 14 mmHg was noted. No significant changes in mean
potassium, glucose, bicarbonate, or pH were seen, with transient mean maximal increases in plasma potassium of
0.3 mmol/L, and mean maximal decreases in blood glucose of 0.8 mmol/L and bicarbonate of 2.3 mEq/L following L-
arginine administration. There was no effect on lactate clearance or RH-PAT index. Pharmacokinetic modelling (n = 4)
showed L-arginine concentrations 40% lower than predicted from models developed in MSM.
Conclusion: In the first clinical trial of an adjunctive treatment aimed at increasing NO bioavailability in severe malaria, L-
arginine infused at 12 g over 8 hours was safe, but did not improve lactate clearance or endothelial NO bioavailability.
Future studies may require increased doses of L-arginine.
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Introduction
The outcome of adults with severe malaria has improved with
use of intravenous artesunate compared to quinine [1,2].
However, case-fatality rates remain as high as 30%, with no
survival benefits noted in the first 48 hours of therapy in adults [1].
Adjunctive agents targeting underlying pathogenesis may be
needed to further improve the outcome. Key mechanisms
underlying the pathogenesis of severe and fatal falciparum malaria
are microvascular obstruction and impaired organ perfusion
resulting from cytoadherence of parasitized red cells to activated
endothelial cells, impaired microvascular reactivity and endothe-
lial dysfunction associated with impaired bioavailability of
endothelial nitric oxide [3,4,5,6].
Nitric oxide (NO) bioavailability is reduced in both African
children with cerebral malaria [7], and Asian and Melanesian
adults with severe falciparum malaria [8]. Mechanisms which may
decrease endothelial NO bioavailability in severe malaria include
impaired nitric oxide synthase 2 (NOS2) expression [7],
hypoargininemia [8,9,10], quenching by cell-free haemoglobin
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[11], and increased concentrations of the nitric oxide synthase
inhibitor, asymmetrical dimethylarginine (ADMA) [12]. Endothe-
lial NO production relies on movement of L-arginine from the
extracellular to intracellular compartment using the cationic
amino acid transporter-1 (CAT-1) with a half-saturating concen-
tration (Km) of 100–150 mmol/L [13]. Plasma L-arginine concen-
trations in severe malaria are low in both African children and
Asian adults and increase with clinical recovery [8,9,10]. We have
previously shown that infusion of L-arginine in doses of 3 g, 6 g
and 12 g over 30 minutes in adults with moderately severe malaria
(MSM) increased endothelial and pulmonary NO bioavailability in
a dose-dependent manner with minimal adverse effects [8,14].
Pharmacokinetic modelling of L-arginine in MSM demonstrated
the half-life of exogenous L-arginine was significantly reduced
compared to healthy adults [15]. Simulations of dosing schedules
predicted a L-arginine dose of 12 g given over 8 hours would
result in concentrations above the Km of CAT-1 in 75% of patients
[15].
There have been no previous clinical studies of agents to
improve NO bioavailability in severe malaria. Based on the safety,
efficacy and pharmacokinetic findings in moderately severe
malaria, we conducted a study of intravenous L-arginine infusion
in Indonesian adults with severe malaria (ARGISM-1 Study). We
evaluated the safety and efficacy profile, including the changes on
vital signs, electrolytes and acid base status, lactate clearance and
endothelial NO bioavailability, and performed a preliminary
pharmacokinetic analysis.
Methods
Study Site, Participants and Ethics Statement
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The ARGISM-1 study was conducted at Mitra
Masyarakat Hospital, Timika, Papua, Indonesia, an area with
unstable malaria transmission. Written informed consent was
obtained from patients or relatives if they were comatose or too ill.
The study was approved by the ethics committees of the National
Institute of Health Research and Development, Indonesia, and the
Menzies School of Health Research, Australia. The study was
registered at clinicaltrials.gov as NTC00616304. The funders had
no role in the study design, data collection, analysis, decision to
publish or preparation of the manuscript.
Patients from 18–60 years of age with severe malaria (SM) were
enrolled. SM was defined as having $1 modified WHO severity
criteria including i) acute renal failure (creatinine.265 mmol/L),
ii) hyperbilirubinemia (total bilirubin.50 mmol/L with either
renal impairment (creatinine.130 mmol/L), or parasitemia of
$100,000/mL), iii) blackwater fever, iv) hyperparasitemia (.10%
parasitized red cells), v) cerebral malaria (Glasgow Coma
Score,11), vi) hypoglycemia (glucose,2.5 mmol/L), vi) respira-
tory distress (respiratory rate.32/min, and the presence of
Plasmodium falciparum parasitemia as used previously [8,16].
Clinical criteria for exclusion included pregnancy or breastfeeding,
systolic blood pressure of ,90 mmHg after fluid resuscitation,
having received anti-malarials longer than 18 hours prior to
admission, significant comorbidities (including diabetes mellitus,
and pre-existing cardiac, renal or hepatic disease), known allergies
to L-arginine, clinical evidence of bacterial infection, current use
of spironolactone, oral nitrates, phosphodiesterase inhibitors,
alpha-blocking antihypertensive agents, and L-arginine. Hemato-
logical and biochemical exclusions were hemoglobin levels of
,60 g/L, venous potassium .5.5 meq/L, chloride.110 meq/L,
and bicarbonate ,15 meq/L.
Study Design
All patients with suspected severe malaria were identified at the
emergency department or outpatient clinics. On confirmation of
severe malaria, patients were screened for any exclusion criteria,
and if negative, informed consent was obtained. Patients were then
randomized in a 2:1 ratio to receive either L-arginine or placebo
with allocation concealed in a sealed opaque envelope. The
randomization sequence and envelopes were prepared by individ-
uals not directly involved in the study. After randomization,
patients underwent a standardized history and physical examina-
tion and were monitored in a high dependency unit for at least 24
hours after the start of intravenous L-arginine or saline infusion. L-
arginine hydrochloride (Phebra, Sydney, Australia) was adminis-
tered as a 12 g dose diluted to 10% in normal saline and given by
an infusion pump over 8 hours, with a similar volume of normal
saline being used in patients randomized to placebo. Patients had
continuous electrocardiogram monitoring throughout and up to
one hour after the end of the infusion. Vital signs including systolic
(SBP) and diastolic blood pressure (DBP), respiratory rate (RR),
pulse rate (PR), Glasgow Coma Score (GCS) and temperature
were recorded at regular intervals during and after infusions.
Oxygen saturation and blood methemoglobin concentrations were
measured using a pulse co-oximeter (Masimo Rad 7, California).
Hemoglobin and leukocyte counts were measured by Coulter
counter at baseline and venous blood was drawn into lithium
heparin tubes at 0, 1, 2, 4, 8, 9, 12 and 24 hours after the start of
infusion. A hand held biochemical analyzer (i-STAT Corp) was
used to measure venous potassium, chloride, bicarbonate and
lactate at these time points [14]. Endothelial function was
measured non-invasively at 0, 1, 8, 9 and 24 hours by the change
in pulse wave amplitude of the digits by peripheral arterial
tonometry (EndoPAT) in response to reactive hyperemia, giving a
RH-PAT Index as described previously [8]. The pulse wave
amplitude in RH-PAT is at least 50% dependent on endothelial
NO production and internal validation and repeatability of RH-
PAT in this population have previously been reported [8,17]. RH-
PAT is also associated with lactate in severe malaria suggesting it
may also reflect function in the systemic microvasculature [8]. We
also measured microvascular reactivity using near infrared
resonance spectroscopy as previously described [6]. All patients
were managed by non-study hospital physicians and treated with
intravenous artesunate and antibiotics using standard hospital
protocols and were followed up until discharge.
Pre-specified criteria for cessation of the infusions were
extravasation, a decrease in the SBP of .25 mmHg from baseline
or to below 80 mmHg, venous potassium of $6.5 meq/L or ECG
changes consistent with hyperkalemia, anaphylaxis, a venous
blood glucose ,3 mmol/L, bicarbonate ,10 meq/L, pH ,7.1 or
methemoglobin level .12%.
L-arginine Concentration Measurements
Venous blood was centrifuged within 20 minutes to obtain
plasma and immediately stored at 270uC. Amino acids were
extracted from 50 ml of plasma after the addition of 50 ml of an
internal standard (norleucine) and 200 ml of cold ethanol.
Deproteinized plasma was derivatized with AccQFluor reagent
(Waters Corp., Milford, MA), and amino acids were measured by
high-performance liquid chromatography (Shimadzu, Kyoto,
Japan) as previously described [8]. The limits of detection were
1.6 mM, and the limit of quantification was 4.9 mM. Inter and
intraday coefficient of variation was 4.1 and 1.2.
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Population Pharmacokinetic Modelling
We used a model derived from a previous study of moderately
severe malaria which was a two compartmental model with first
order elimination [15], as an initial construct to explore the data
from the patients with severe malaria. A first order conditional
estimation method with interaction was used to analyse the data
using NONMEM (version 6), with the G77 FORTRAN compiler.
Model suitability was evaluated with standard goodness-of-fit
criteria including objective function, parameter estimates, be-
tween-subject variability and diagnostic plots. Compartmental
models were parameterized in terms of volumes of distribution (V),
and clearances.
Statistical Methods
Mean values of the vital signs and biochemical parameters
before infusion were compared to mean values obtained during
and after infusion using a paired t-test (for continuous variables
with a normal distribution or variables log transformed to a
normal distribution). If parameters were not normally distributed,
values before and after infusion were compared by the Wilcoxon
Signed Rank Test. Because analysis in this manner could mask
transient but potentially clinically significant changes in a minority
of subjects, we also analyzed the maximum change in the vital
signs and biochemical markers at any time during and up to two
hours after L-arginine infusion compared to baseline readings.
This gave a ‘‘worst-case scenario’’, however transient, for each
marker. The mean of the pre-infusion values in each patient was
subtracted from the lowest (SBP, DBP, glucose, bicarbonate, pH)
and highest (pulse rate, respiratory rate, potassium, chloride and
anion gap) measurement during infusion or in the two hours
following infusion and expressed as mean maximum change.
Relationships between maximum change and the dose weight
ratio (calculated as mg/kg) were assessed by Spearman’s rank
correlation coefficient (r). Sample size calculation estimated 20
patients should be randomized to L-arginine and 8 to saline to
detect a 20 per cent difference in endothelial function. All analyses
were performed with Stata 11 (Statacorp). A two sided value of
p,0.05 was considered significant.
Results
Patients
Eight patients were enrolled in the study from 1st February 2008
to 28th February 2009; six received L-arginine and two, saline
(Figure 1). Local circumstances, including difficulties in accessing
the field site, prevented continuation of the study but did not affect
the preceding conduct of the study. In patients who received L-
arginine, four had one severity criterion (three with cerebral
malaria and one with hyperbilirubinemia), one had two criteria
(acute renal failure and hyperbilirubinemia) and one had four
severity criteria (cerebral malaria, acute renal failure, hyperbiliru-
binemia, and blackwater fever). In those who received saline, one
patient had one severity criterion (cerebral malaria) and one had
four criteria (cerebral malaria, respiratory distress, hyperbilirubin-
emia, and hyperparasitemia). All the patients were treated with
intravenous artesunate and six received additional antibiotics. One
patient with acute renal failure received peritoneal dialysis but
went on to recover renal function, and there were no deaths in the
study. The patients’ baseline details are shown in Table 1.
Clinical Adverse Effects during L-arginine Infusion
There were no significant clinical adverse effects in any patient;
in particular, there were no allergic reactions, convulsions, pain,
rash, swelling or erythema at the infusion site. In the two patients
who were not comatose, there was no increase in severity of
nausea, vomiting, headache or prostration during or after the L-
arginine infusion.
Effect of L-arginine on Vital Signs, Cardiac Rhythm,
Concentrations of Methemoglobin
There was no difference in coma recovery times between
patients who received L-arginine (mean 35 hours [range 12–69
hours]) and those who received saline (34 and 40 hours). There
was no significant effect on the mean pulse and respiratory rate
before and after infusion of L-arginine and there were no notable
changes on the electrocardiogram. There were no clinically
significant changes in the mean systolic or diastolic blood pressure
during and up to 16 hours after the end of the infusion in patients
who received L-arginine (Figure 2A and 2B) or saline. However,
the mean maximum change in the systolic blood pressure during the
infusion in those who received L-arginine was-14 mmHg (range
211 to 219 mmHg) (paired T-test, p,0.001) compared to
20.5 mmHg (range 0 to 21 mmHg) with saline; Table 2. The
change in the mean maximal diastolic blood pressure in those
receiving L-arginine was 212 mmHg, (range 26 to 216 mmHg)
(paired T-test; p = 0.003) compared to 26 mmHg (range 22 to
210 mmHg) with saline; Table 2. There was a significant
correlation between the maximal fall in systolic (r=20.82,
p = 0.04) and diastolic (r=20.85, p = 0.03) blood pressure with
increasing mg per kg L-arginine doses. There were no differences
noted in the maximum changes in pulse rate, respiratory rate and
methemoglobin levels between the groups.
Effect of L-arginine on Electrolytes, pH and Glucose
There were no clinically significant changes in the mean values
of potassium, chloride, glucose, pH, anion gap and bicarbonate
during and up to 16 hours after infusion compared to pre-infusion
levels; Figure 3A, 3B, 3C and 3D. Significant but transient and
clinically unimportant differences (by paired T-test) were noted in
the maximal change of potassium, chloride and glucose following
L-arginine infusion, Table 2. The mean baseline bicarbonate
concentrations or pH in those that received L-arginine or saline
are shown in Table 1 and the maximal decreases in bicarbonate
and pH in Table 2. There was no relationship noted between the
maximal change in potassium, chloride, glucose or bicarbonate
with increasing mg per kg L-arginine doses.
Effect of L-arginine on Lactate Clearance and Endothelial
Function
Only 5 patients (4 L-arginine and 1 saline) had elevated blood
lactate (.2 mmol/L) at baseline, with the baseline lactate being
higher in the two patients randomized to receive saline Table 1.
The lactate clearance rate did not appear to be different between
the patients who received L-arginine or saline, however the small
numbers of patients did not allow us to formally compare the
groups. Six patients (4 L-arginine and 2 saline) had impaired
endothelial function (defined as RH-PAT index ,1.67) at
baseline. There was also no difference in the change in endothelial
function during and up to one hour after infusion of L-arginine
(p = 0.3) or saline compared to baseline; Figure 4. There was also
no change in microvascular reactivity during and after L-arginine
infusion.
Preliminary Pharmacokinetics of L-arginine after Infusion
National changes in the implementation of pre-existing
materials transfer agreements pertaining to sample export meant
that serial measures of L-arginine could only be measured in the
L-Arginine Infusion in Severe Falciparum Malaria
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Figure 1. Flow diagram of patients screened and enrolled for the ARGISM-1 study.
doi:10.1371/journal.pone.0069587.g001
Table 1. Baseline characteristics and laboratory results in severe malaria patients.
L-arginine Infusion Group Saline Infusion Group
Number of patients 6 2
Mean age (year; range) 31.5 (18 to 55) 35.5 (27 to 44)
No (%) of males 4 (66%) 2 (100%)
Mean weight (kg; range) 59 (45 to 70) 57.5 (55 to 60)
No (%) of Papuan Highlanders 4 (66%) 2 (100%)
Mean no of days before admission (range) 1.2 (1 to 2) 1 (1 to 1)
Mean systolic blood pressure (mmHg; range) 115 (94 to 141) 106 (98 to 114)
Mean pulse rate (beats/minute; range) 87 (74 to 99) 88 (81 to 95)
Mean respiratory rate (breaths/min; range) 23 (21 to 25) 28 (24 to 32)
Mean temperature (uC; range) 36.9 (36.3 to 38) 36.3 (36.2 to 36.4)
Mean methemoglobin level (%; range) 1.2 (0.9 to 1.8) 1.2 (1.1 to 1.3)
Mean leukocyte count (103/mL, range) 10.3 (7.4 to 11.9) 9.1 (7.1 to 11.1)
Mean haemoglobin count (g/dl, range) 13.2 (12.9 to 14.3) 13.7 (11.6 to 16.3)
Mean L-arginine plasma concentration (mmol/L, range) 56 (32 to 95) 62 (48 to 76)
Mean lactate concentration (mmol/L, range) 2.3 (1.2 to 3.3) 3.8 (3.3 to 4.4)
Mean bicarbonate concentration (mmol/L; range) 22.7 (17.4 to 26.9) 20.7 (18.6 to 22.8)
Mean potassium concentration (mmol/L; range) 3.8 (3.5 to 4.1) 3.8 (3.8 to 3.8)
Mean glucose concentration (mmol/L; range) 6.6 (4 to 9.2) 6.85 (5.6 to 8.1
Mean plasma phosphate (meq/L; range) 1.2 (0.6 to 2.5) 1.1 (0.7 to 1.5)
Geometric mean parasite density (parasites/mL; range) 42300 (6660 to 148296) 258505 (95359 to 700848)
doi:10.1371/journal.pone.0069587.t001
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first five of the eight patients enrolled (four L-arginine and one
saline). These results represent a preliminary assessment of the
pharmacokinetic behavior of L-arginine in patients with SM and
the time-concentration curves for plasma L-arginine concentra-
tions are shown in Figure 5. In these analyses we used the same 2-
compartment structural model with a polynomial model for
placebo (patients who did not receive arginine) as was used in the
previous population pharmacokinetic analysis of patients with
moderately severe malaria [15]. For this preliminary data set the
values of peripheral volume and intercompartmental clearance
were fixed as their values could not be estimated based on the data
from five patients. The fixed effects values of the change from
baseline of L-arginine in the patient who received only saline were
estimated based on the model from MSM and the parameter
values were found to be similar to those for MSM. This model
provided an acceptable description of the L-arginine data, based
on individual plots of predicted and observed data versus time,
from the 5 SM patients. From data from the 4 patients who
received L-arginine infusion, the between subject variance (BSV)
was able to be estimated for clearance (CL) only. The data would
not support consideration of BSV terms on other parameters (such
as baseline and V1). Pharmacokinetic parameters derived from the
severe malaria patients are presented in table 3 and compared
with those previously derived in moderately severe malaria. There
were too few patients in this study to consider the influence of
covariates.
Discussion
This is the first clinical trial of an adjunctive treatment aimed at
increasing NO bioavailability in severe malaria. In this study L-
arginine was given intravenously to adults with severe falciparum
malaria at the dose of 12 g over 8 hours. There were no clinically
significant adverse effects on symptoms, vital signs, selected
biochemical measures and acid base status. No improvements in
lactate clearance time or endothelial function were noted, though
only 4 of 6 patients who received L-arginine had abnormal baseline
values for lactate and endothelial function. Pharmacokinetic analysis
of L-arginine demonstrated the clearance was approximately 40%
higher in severe malaria, with concentrations lower than those
predicted from a previous model developed in moderately severe
malaria [15]. However, the small numbers of patients in each group
do not permit us to make definite conclusions.
The effects of L-arginine in decreasing blood pressure are
thought to be due to increased endothelial nitric oxide (NO)
production [18]. The lack of decrease in mean blood pressure with
L-arginine infused at 1.5 g/hour contrasted with the findings from
our previous study in MSM where 12 g was given at a rate of
24 g/hour. In that study, a decrease in the mean systolic and
diastolic pressure was noted towards the end of the 12 g but not
the 3 g or 6 g infusions. However, our results are in agreement
with a study of adult sepsis given L-arginine at 1.1 g/hour for 3
days [19], where no hemodynamic effects were reported. In
contrast to the lack of change in mean systolic BP, there was a
transient but statistically significant change in mean maximal
decrease in systolic and diastolic blood pressure following L-
arginine infusion. Both were highly correlated with the L-arginine
dose/body weight ratio, suggesting a transient dose-related
increase in NO production.
Consistent with our previous study, there was no statistically
significant change in the mean plasma potassium concentrations,
but a transient and statistically significant but clinically unimpor-
tant mean maximal increase in potassium concentration in
patients given L-arginine compared to pre-infusion levels. The
mean maximal ranges of increase were 0.2 to 0.7 meq/L and no
patient had a potassium concentration higher than 5 meq/L,
including the patients with acute renal failure. This was
comparable to increases previously seen in patients with moder-
ately-severe malaria given 6 g over 30 minutes but lower than
those given 12 g in the same time period [14]. The increase is
thought to result from increased L-arginine uptake by the cells
Figure 2. a. Profile of the systolic blood pressure of patients before,
during and one hour after receiving L-arginine. Dotted lines indicate
patients who received saline. L-arginine was infused between zero and
eight hours. b. Profile of the diastolic blood pressure of patients before,
during and one hour after receiving L-arginine. Dotted lines indicate
patients who received saline.
doi:10.1371/journal.pone.0069587.g002
Table 2. Maximum change in parameters at any time during
and up to one hour after L-arginine infusion.
L-arginine Saline
SBP (mmHg) 214 (211 to 220) 21 (21 to 21)
DBP (mmHg) 212 (26 to 215) 26 (22 to 210)
Potassium (mmol/L) 0.3 (0.2 to 0.7) 20.1 (20.2 to 20.1)
Bicarbonate (meq/L) 22.3 (0 to 24.4) 0.5 (21 to 2)
pH 20.02 (20.007 to 20.04) 0.03 (0 to 0.07)
Chloride (mmol/L) 2.8 (2 to 3) 2.5 (0 to5)
Glucose (mmol/L) 20.8 (21.4 to 20.1) 1.05 (0.4 to 1.7)
Mean maximum change (range).
doi:10.1371/journal.pone.0069587.t002
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with subsequent movement of intracellular potassium to the
extracellular space [20]. There was also a statistically significant
but clinically unimportant mean maximal decrease in glucose
concentration, but again not when mean change was evaluated.
These changes were again consistent with those seen in our
previous study and were not close to the range where replacement
is required. The lack of a clear dose relationship between L-
arginine for both the maximal increase in potassium and the
decrease in glucose may also indicate that L-arginine was not
causal and that other mechanisms may be involved.
The only commercially available intravenous L-arginine
formulation is the hydrochloride form which contains 4.75 meq
of hydrogen and chloride ions per gram. In MSM patients, there
was a dose-dependent relationship between L-arginine with
decreases in bicarbonate and pH, and an increase in chloride
[14]. In this pilot study, patients with metabolic acidosis with
bicarbonate concentrations of less than 15 meq/L were excluded.
There was a transient statistically significant decrease in
bicarbonate concentrations in the maximal but not mean change
following L-arginine infusion. There was also a significant but
clinically unimportant mean maximal increase in chloride of
2.8 mmol/L compared to baseline, although this was not different
to the 2.5 mmol/L change seen in those given saline. The lack of
change in the pH and lactate suggest that the effect on overall acid
base status was clinically unimportant. The stable anion gap and
increase in chloride suggests the bicarbonate decrease was due to
hydrogen and chloride contained in the L-arginine. Other agents
used to increase NO bioavailability such as inhaled NO, can
Figure 3. a. Profile of the venous potassium concentration of patients
before, during and three hours after receiving L-arginine. Broken lines
indicate patients with acute renal failure and dotted lines indicate
patients who received saline. L-arginine was infused between zero and
eight hours. b. Profile of the venous bicarbonate concentrations of
patients before, during and three hours after receiving L-arginine.
Broken lines indicate patients with acute renal failure and dotted lines
indicate patients who received saline. c. Profile of the venous blood
glucose concentrations of patients before, during and three hours after
receiving L-arginine. Broken lines indicate patients with acute renal
failure and dotted lines indicate patients who received saline. d. Profile
of the venous blood chloride concentrations of patients before, during
and three hours after receiving L-arginine. Broken lines indicate patients
with acute renal failure and dotted lines indicate patients who received
saline.
doi:10.1371/journal.pone.0069587.g003
Figure 4. RH-PAT index profile pre-infusion, one hour and
eight hours after infusion of L-arginine. Dotted lines indicate
patients who received saline.
doi:10.1371/journal.pone.0069587.g004
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increase methemoglobin [21]. No increase in methemoglobin was
seen following L-arginine infusion.
We did not find any improvement in the lactate clearance time,
and in contrast to our study in MSM, there was no increase in
endothelial NO production [8]. Previously, L-arginine was given
in MSM over 30 minutes in ascending doses at rates of 6 g/hour
to 24 g/hour compared to the 1.5 g/hour rate in this study in
severe malaria. Simulations from a pharmacokinetic model of L-
arginine infusion developed in MSM predicted that the dose used
in the current study would deliver L-arginine concentrations above
the Km of the CAT-1 transporter in 70% of the patients [15].
However, pharmacokinetic analysis in SM showed that the
concentrations achieved in the current study were 40 percent
lower than expected. This may be due to the increased plasma
arginase concentrations found in SM compared to MSM [8], and
may have contributed to the lack of endothelial response. Other
factors could play a role in reducing vascular NO bioavailability in
SM compared to MSM, including increased concentrations of the
endogenous NOS inhibitor asymmetrical dimethylarginine
(ADMA) [12], and increased NO quenching by cell-free hemo-
globin [11]. The adequacy of concentrations of the NOS cofactor,
tetrahydrobiopterin, in severe malaria also requires further
investigation. Our results suggest that future studies of L-arginine
in SM will require an increase in the dosage.
The structural model derived from moderately severe malaria
appears to describe the data in severe malaria accurately. Although
the small numbers of patients in whom pharmacokinetic assessment
was possible limited the ability to determine accurate estimates of
pharmacokinetic parameters, typical population values of CL andV
appeared to be ,40% and ,400% larger for patients with severe
malaria compared to the previous study inMSM[15]. Limitations in
available subjects may have led to potential bias in the values of the
parameters. It is likely thatdoseadjustmentmaybeneeded inpatients
with SM compared toMSM.
In summary, a 12 g dose of L-arginine infused at 1.5 g/hour for
8 hours in patients with SM was safe, well tolerated and resulted in
statistically significant but transient and clinically insignificant
effects on mean maximal change in systolic blood pressure,
potassium, glucose, bicarbonate and chloride compared to pre-
infusion levels. Although numbers were small and there were only
modest baseline abnormalities in lactate concentrations and
endothelial function, no improvement in lactate clearance or
endothelial function were seen. Notably plasma L-arginine
concentrations following infusion appeared to be 40 percent lower
than predicted. Future studies in SM will require an increase in the
dosage of L-arginine.
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Figure 5. Time-concentration curves for plasma L-arginine
concentrations before and after infusion of 12 g L-arginine
(solid line) or saline (broken line) for patients 1 to 5. X-
axis = time in hours, y-axis = L-arginine concentration in mg/L.
doi:10.1371/journal.pone.0069587.g005
Table 3. Pharmacokinetic parameter values estimated in the
patients with severe malaria compared to those from
moderately severe malaria [15].
Parameter
Moderately severe
malaria (ref [15])
Severe
malaria
Structural model parameters for L-arginine
CL (L/h) 31 61.8
V1 (L) 27 115
V2 (L) 21 70.9 (fixed)
Q (L/h) 74 21.4 (fixed)
Structural model parameters for natural recovery of L-arginine
Base 33 5.88
Gradient 1 0.0612 0.153
Gradient 2 20.139 20.492
Variability between patients
BSV CL (%) 0.274 0.116
BSV V1 (%) 0.0103 0.0103 (fixed)
BSV BL (%) 0.163 0.163 (fixed)
Residual variability
s (proportional) 28.6% 22.5%
The moderate severe malaria parameter estimates are derived from the best
model without considering covariates (for comparison with the current
parameter estimates).
Baseline = base+gradient(1)*time+gradient(2)*time2. Where time represents
time post-start of L-arginine infusion.
CL = clearance, V1 = central volume of distribution, V2 = peripheral volume of
distribution, Q= intercompartmental clearance, BSV = between subject
variability which was assumed to be log-normally distribution and expressed as
a %, s= residual variability (standard deviation).
doi:10.1371/journal.pone.0069587.t003
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